Wilms tumor trials

This phase II Pediatric MATCH trial studies how well olaparib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with defects in deoxyribonucleic acid DNA damage repair genes that have spread to other places in the body advanced and have come back relapsed or do not respond to treatment refractory.

PARP inhibitors are a type of targeted therapy. This phase II Pediatric MATCH trial studies how well palbociclib works in treating patients with Rb positive solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with activating alterations mutations in cell cycle genes that have spread to other places in the body and have come back or do not respond to treatment.

Palbociclib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Samotolisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. This phase II pediatric MATCH trial studies how well selpercatinib works in treating patients with solid tumors that have spread to other places in the body advanced , lymphomas, or histiocytic disorders that have activating RET gene alterations.

Selpercatinib may block the growth of cancer cells that have specific genetic changes in an important signaling pathway called the RET pathway and may reduce tumor size. This research trial studies kidney tumors in younger patients. Collecting and storing samples of tumor tissue, blood, and urine from patients with cancer to study in the laboratory may help doctors learn more about changes that occur in deoxyribonucleic acid DNA and identify biomarkers related to cancer.

Genetic tests look at the unique genetic material genes of patients' tumor cells. Patients with genetic changes or abnormalities mutations may benefit more from treatment which targets their tumor's particular genetic mutation, and may help doctors plan better treatment for patients with solid tumors or non-Hodgkin lymphomas. This phase II pediatric MATCH trial studies how well tipifarnib works in treating patients with solid tumors that have recurred or spread to other places in the body advanced , lymphoma, or histiocytic disorders, that have a genetic alteration in the gene HRAS.

Tipifarnib may block the growth of cancer cells that have specific genetic changes in a gene called HRAS and may reduce tumor size. I am looking for tumor markers. I am looking for growth factor.

I am looking for interleukins. I am looking for radiopharmaceutical. I am looking for interferon. I am looking for corticosteroids. I am looking for cytokines. I am looking for biologic agent. I am looking for experimental drug. I am looking for colony-stimulating factors. I am looking for be Search by keywords:.

Previous Wilms' Tumor Treatment. Next Wilms' Tumor Support. At MSK, we focus exclusively on cancer. This phase II trial studies how well cabozantinib-s-malate works in treating younger patients with sarcomas, Wilms tumor, or other rare tumors that have come back, do not respond to therapy, or are newly diagnosed.

Cabozantinib-s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for tumor growth and tumor blood vessel growth. This phase II trial is studying the side effects and how well cixutumumab works in treating patients with relapsed or refractory solid tumors. Monoclonal antibodies, such as cixutumumab, can block tumor growth in different ways.

Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them.